Citations (166)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Yann-Alexandre Vano, Eric Tartour, Laure S Fournier, Benoit Beuselinck, Arnaud Mejean & Stephane Oudard. (2014) Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents. Expert Review of Anticancer Therapy 14:5, pages 523-542.
Read now
Read now
Xiao-fen Li, Mo-dan Li, Hong Shen, Xue-feng Fang, Pin-tong Huang & Ying Yuan. (2012) Evaluation of therapeutic effect of tumor-targeted therapy. OncoTargets and Therapy 5, pages 191-198.
Read now
Read now
Viktor Grünwald & Axel S Merseburger. (2012) Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment. OncoTargets and Therapy 5, pages 111-117.
Read now
Read now
Risto A. Kauppinen & Andrew C. Peet. (2011) Using magnetic resonance imaging and spectroscopy in cancer diagnostics and monitoring. Cancer Biology & Therapy 12:8, pages 665-679.
Read now
Read now
Articles from other publishers (162)
Sarah J. Welsh, Nicola Thompson, Anne Warren, Andrew N. Priest, Tristan Barrett, Stephan Ursprung, Ferdia A. Gallagher, Fulvio Zaccagna, Grant D. Stewart, Kate M. Fife, Athena Matakidou, Andrea J. Machin, Wendi Qian, Victoria Ingleson, Jean Mullin, Antony C. P. Riddick, James N. Armitage, Stephen Connolly & Timothy G. Q. Eisen. (2021) Dynamic biomarker and imaging changes from a phase II study of pre‐ and post‐surgical sunitinib. BJU International 130:2, pages 244-253.
Crossref
Crossref
Ankita Aggarwal, Chandan J Das & Sanjay Sharma. (2022) Recent advances in imaging techniques of renal masses. World Journal of Radiology 14:6, pages 137-150.
Crossref
Crossref
Sourav Bhaduri, Clémentine Lesbats, Jack Sharkey, Claire Louise Kelly, Soham Mukherjee, Arthur Taylor, Edward J. Delikatny, Sungheon G. Kim & Harish Poptani. (2022) Assessing Tumour Haemodynamic Heterogeneity and Response to Choline Kinase Inhibition Using Clustered Dynamic Contrast Enhanced MRI Parameters in Rodent Models of Glioblastoma. Cancers 14:5, pages 1223.
Crossref
Crossref
Ching-Chung Ko, Lee-Ren Yeh, Yu-Ting Kuo & Jeon-Hor Chen. (2021) Imaging biomarkers for evaluating tumor response: RECIST and beyond. Biomarker Research 9:1.
Crossref
Crossref
Chengyue Wu, David A. HormuthIIII, Ty Easley, Victor Eijkhout, Federico Pineda, Gregory S. Karczmar & Thomas E. Yankeelov. (2021) An in silico validation framework for quantitative DCE-MRI techniques based on a dynamic digital phantom. Medical Image Analysis 73, pages 102186.
Crossref
Crossref
Seiichiro Takao, Yasuhiro Ushijima, Yushi Motomura, Katsumi Sakamoto, Masakazu Hirakawa, Akihiro Nishie, Koshi Mimori, Yasuo Yamashita, Takashi Tsutsumi & Kousei Ishigami. (2021) Radiology- and gene-based risk stratification in small renal cell carcinoma: A preliminary study. PLOS ONE 16:9, pages e0256471.
Crossref
Crossref
Durga Udayakumar, Ze Zhang, Yin Xi, Durgesh K. Dwivedi, Michael Fulkerson, Sydney Haldeman, Tiffani McKenzie, Qurratulain Yousuf, Allison Joyce, Asghar Hajibeigi, Hollis Notgrass, Alberto Diaz de Leon, Qing Yuan, Matthew A. Lewis, Ananth J. Madhuranthakam, Robert C. Sibley, Roy Elias, Junyu Guo, Alana Christie, Renée M. McKay, Jeffrey A. Cadeddu, Aditya Bagrodia, Vitaly Margulis, James Brugarolas, Tao Wang, Payal Kapur & Ivan Pedrosa. (2021) Deciphering Intratumoral Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma with a Radiogenomics Platform. Clinical Cancer Research 27:17, pages 4794-4806.
Crossref
Crossref
Yu He, Yang Luo, Lan Huang, Dan Zhang, Xixi Wang, Jiayi Ji & Shufang Liang. (2021) New frontiers against sorafenib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers. Pharmacological Research 170, pages 105732.
Crossref
Crossref
Martina Caruso, Valeria Romeo, Arnaldo Stanzione, Carlo Buonerba, Giuseppe Di Lorenzo & Simone Maurea. (2021) Current Imaging Evaluation of Tumor Response to Advanced Medical Treatment in Metastatic Renal-Cell Carcinoma: Clinical Implications. Applied Sciences 11:15, pages 6930.
Crossref
Crossref
Jim Zhong, Ebrahim Palkhi, David L. Buckley, Fiona J. Collinson, Christy Ralph, Satinder Jagdev, Naveen S. Vasudev, Jayne Swain, Janet E. Brown & Tze Min Wah. (2021) Feasibility Study on Using Dynamic Contrast Enhanced MRI to Assess the Effect of Tyrosine Kinase Inhibitor Therapy within the STAR Trial of Metastatic Renal Cell Cancer. Diagnostics 11:7, pages 1302.
Crossref
Crossref
Jeong Kon Kim. 2021. Advanced Imaging and Bio Techniques for Convergence Science. Advanced Imaging and Bio Techniques for Convergence Science
187
209
.
Lulu Xu, Xiaolin Ge, Nana Sun & Xisheng Liu. (2020) Dynamic contrast-enhanced MRI histogram parameters predict progression-free survival in patients with advanced esophageal squamous carcinoma receiving concurrent chemoradiotherapy. Acta Radiologica 61:10, pages 1316-1325.
Crossref
Crossref
Kevin D. Courtney, Yuanqing Ma, Alberto Diaz de Leon, Alana Christie, Zhiqun Xie, Layton Woolford, Nirmish Singla, Allison Joyce, Haley Hill, Ananth J. Madhuranthakam, Qing Yuan, Yin Xi, Yue Zhang, Jenny Chang, Oluwatomilade Fatunde, Yull Arriaga, Arthur E. Frankel, Sanjeeva Kalva, Song Zhang, Tiffani McKenzie, Oscar Reig Torras, Robert A. Figlin, Brian I. Rini, Renée M. McKay, Payal Kapur, Tao Wang, Ivan Pedrosa & James Brugarolas. (2020) HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma. Clinical Cancer Research 26:4, pages 793-803.
Crossref
Crossref
Yong Chen, Muhummad Sohaib Nazir, Sebastian Kozerke, Sven Plein & Shivani Pahwa. 2020. Quantitative Magnetic Resonance Imaging. Quantitative Magnetic Resonance Imaging
427
454
.
Jörg Stattaus, Michael Forsting & Axel Wetter. 2020. Uroonkologie. Uroonkologie
1
14
.
Alberto Conficoni, Antonio Poerio, Eleonora Farina & Alessio G. Morganti. 2020. Imaging and Interventional Radiology for Radiation Oncology. Imaging and Interventional Radiology for Radiation Oncology
293
323
.
Yichen Wang, Liqiang Cui, Jin Zhang, Lianyu Zhang, Jie Zhang, Xinming Zhao & Yan Chen. (2019) Baseline perfusion CT parameters as potential biomarkers in predicting long-term prognosis of localized clear cell renal cell carcinoma. Abdominal Radiology 44:10, pages 3370-3376.
Crossref
Crossref
Alberto Diaz de Leon, Payal Kapur & Ivan Pedrosa. (2019) Radiomics in Kidney Cancer. Magnetic Resonance Imaging Clinics of North America 27:1, pages 1-13.
Crossref
Crossref
Shivashankar Damodaran & E. Jason Abel. 2019. Diagnosis and Surgical Management of Renal Tumors. Diagnosis and Surgical Management of Renal Tumors
247
262
.
Gordon Jayson & James O’Connor. 2019. Tumor Angiogenesis. Tumor Angiogenesis
277
290
.
Amir H. Lebastchi, Matthew J. Watson, Christopher M. Russell, Arvin K. George, Alon Z. Weizer & Baris Turkbey. (2018) Using Imaging to Predict Treatment Response in Genitourinary Malignancies. European Urology Focus 4:6, pages 804-817.
Crossref
Crossref
Nicole Wake, Hersh Chandarana, Henry Rusinek, Koji Fujimoto, Linda Moy, Daniel K. Sodickson & Sungheon Gene Kim. (2018) Accuracy and precision of quantitative DCE-MRI parameters: How should one estimate contrast concentration?. Magnetic Resonance Imaging 52, pages 16-23.
Crossref
Crossref
John M. Hudson, Colleen Bailey, Mostafa Atri, Greg Stanisz, Laurent Milot, Ross Williams, Alex Kiss, Peter N. Burns & Georg A. Bjarnason. (2018) The prognostic and predictive value of vascular response parameters measured by dynamic contrast-enhanced-CT, -MRI and -US in patients with metastatic renal cell carcinoma receiving sunitinib. European Radiology 28:6, pages 2281-2290.
Crossref
Crossref
Jie Chen, Chenyang Chen, Chunchao Xia, Zixing Huang, Panli Zuo, Alto Stemmer & Bin Song. (2017) Quantitative free-breathing dynamic contrast-enhanced MRI in hepatocellular carcinoma using gadoxetic acid: correlations with Ki67 proliferation status, histological grades, and microvascular density. Abdominal Radiology 43:6, pages 1393-1403.
Crossref
Crossref
Kazuhiro Saito, Joseph Ledsam, Katsutoshi Sugimoto, Steven Sourbron, Yoichi Araki & Koichi Tokuuye. (2018) DCE-MRI for Early Prediction of Response in Hepatocellular Carcinoma after TACE and Sorafenib Therapy: A Pilot Study. Journal of the Belgian Society of Radiology 102:1.
Crossref
Crossref
Christian Kelly-Morland, Gary Cook & Vicky Goh. 2018. PET/MRI in Oncology. PET/MRI in Oncology
131
150
.
Christian Kelly-Morland, Sarah Rudman, Paul Nathan, Susan Mallett, Giovanni Montana, Gary Cook & Vicky Goh. (2017) Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated 18F?Fluorodeoxyglucose (18F?FDG) positron emission tomography/magnetic resonance imaging (PET/MRI); The REMAP study. BMC Cancer 17:1.
Crossref
Crossref
Ananth J. Madhuranthakam, Qing Yuan & Ivan Pedrosa. (2017) Quantitative Methods in Abdominal MRI. Topics in Magnetic Resonance Imaging 26:6, pages 251-258.
Crossref
Crossref
Alberto Diaz de Leon & Ivan Pedrosa. (2017) Imaging and Screening of Kidney Cancer. Radiologic Clinics of North America 55:6, pages 1235-1250.
Crossref
Crossref
Thomas B. Karasic, Mark A. Rosen & Peter J. O’Dwyer. (2017) Antiangiogenic tyrosine kinase inhibitors in colorectal cancer: is there a path to making them more effective?. Cancer Chemotherapy and Pharmacology 80:4, pages 661-671.
Crossref
Crossref
Simon P. Robinson, Jessica K.R. Boult, Naveen S. Vasudev & Andrew R. Reynolds. (2017)
Monitoring the Vascular Response and Resistance to Sunitinib in Renal Cell Carcinoma
In Vivo
with Susceptibility Contrast MRI
. Cancer Research 77:15, pages 4127-4134.
Crossref
Crossref
Atul B. ShinagareKatherine M. KrajewskiMarta Braschi-AmirfarzanNikhil H. Ramaiya. (2017) Advanced Renal Cell Carcinoma: Role of the Radiologist in the Era of Precision Medicine. Radiology 284:2, pages 333-351.
Crossref
Crossref
Frank I. Lin, Erich P. Huang & Lalitha K. Shankar. (2017) Beyond Correlations, Sensitivities, and Specificities. Academic Radiology 24:8, pages 1027-1035.
Crossref
Crossref
Qingbo Yin, Sheng-Che Hung, Li Wang, Weili Lin, Julia R. Fielding, W. Kimryn Rathmell, Amir H. Khandani, Michael E. Woods, Matthew I. Milowsky, Samira A. Brooks, Eric. M. Wallen & Dinggang Shen. (2017) Associations between Tumor Vascularity, Vascular Endothelial Growth Factor Expression and PET/MRI Radiomic Signatures in Primary Clear-Cell–Renal-Cell-Carcinoma: Proof-of-Concept Study. Scientific Reports 7:1.
Crossref
Crossref
Jie Deng & Yi Wang. (2017) Quantitative magnetic resonance imaging biomarkers in oncological clinical trials: Current techniques and standardization challenges. Chronic Diseases and Translational Medicine 3:1, pages 8-20.
Crossref
Crossref
Gordon Jayson & James O’Connor. 2017. Tumor Angiogenesis. Tumor Angiogenesis
1
14
.
Bang-Bin Chen, Chao-Yu Hsu, Chih-Wei Yu, Po-Chin Liang, Chiun Hsu, Chih-Hung Hsu, Ann-Lii Cheng & Tiffany Ting-Fang Shih. (2016) Dynamic Contrast-enhanced MR Imaging of Advanced Hepatocellular Carcinoma: Comparison with the Liver Parenchyma and Correlation with the Survival of Patients Receiving Systemic Therapy. Radiology 281:2, pages 454-464.
Crossref
Crossref
Yeo-Eun Kim, Bio Joo, Mi-Suk Park, Sang Joon Shin, Joong Bae Ahn & Myeong-Jin Kim. (2016) Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for Bevacizumab in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial. Cancer Research and Treatment 48:4, pages 1210-1221.
Crossref
Crossref
Afshin Dowlati, Gordana Vlahovic, Ronald B. Natale, Erik Rasmussen, Indrajeet Singh, Yuying C. Hwang, John Rossi, Michael B. Bass, Gregory Friberg & Cheryl A. Pickett. (2016) A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research 22:18, pages 4574-4584.
Crossref
Crossref
Katherine M. Krajewski & Atul B. Shinagare. (2016) Novel imaging in renal cell carcinoma. Current Opinion in Urology 26:5, pages 388-395.
Crossref
Crossref
Yu Sub Sung, Bumwoo Park, Yoonseok Choi, Hyeong-Seok Lim, Dong-Cheol Woo, Kyung Won Kim & Jeong Kon Kim. (2016) Dynamic contrast-enhanced MRI for oncology drug development. Journal of Magnetic Resonance Imaging 44:2, pages 251-264.
Crossref
Crossref
Francois Cornelis, Anne-Sophie Lasserre, Elise Tricaud, Francois Petitpierre, Yann Le Bras & Nicolas Grenier. 2016. Imaging of the Pelvis, Musculoskeletal System, and Special Applications to CAD. Imaging of the Pelvis, Musculoskeletal System, and Special Applications to CAD
1
36
.
Ka-Loh Li, Ibrahim Djoukhadar, Xiaoping Zhu, Sha Zhao, Simon Lloyd, Martin McCabe, Catherine McBain, D. Gareth Evans & Alan Jackson. (2016) Vascular biomarkers derived from dynamic contrast-enhanced MRI predict response of vestibular schwannoma to antiangiogenic therapy in type 2 neurofibromatosis. Neuro-Oncology 18:2, pages 275-282.
Crossref
Crossref
Ahmed Salem & James P.B. O’Connor. (2016) Assessment of Tumor Angiogenesis. Magnetic Resonance Imaging Clinics of North America 24:1, pages 45-56.
Crossref
Crossref
Roberto García-Figueiras, Anwar R. Padhani & Sandra Baleato-González. (2016) Therapy Monitoring with Functional and Molecular MR Imaging. Magnetic Resonance Imaging Clinics of North America 24:1, pages 261-288.
Crossref
Crossref
F.L. Besson, V. Lebon & E. Durand. (2016) What are we expecting from PET/MRI?. M?decine Nucl?aire 40:1, pages 31-40.
Crossref
Crossref
Yue Zhang, Payal Kapur, Qing Yuan, Yin Xi, Ingrid Carvo, Sabina Signoretti, Ivan Dimitrov, Jeffrey A. Cadeddu, Vitaly Margulis, Naira Muradyan, James Brugarolas, Ananth J. Madhuranthakam & Ivan Pedrosa. (2016) Tumor Vascularity in Renal Masses: Correlation of Arterial Spin-Labeled and Dynamic Contrast-Enhanced Magnetic Resonance Imaging Assessments. Clinical Genitourinary Cancer 14:1, pages e25-e36.
Crossref
Crossref
Saelin OhDeuk Jae Sung. (2016) Current MR Imaging of Renal Cell Carcinoma. Journal of the Korean Society of Radiology 75:2, pages 77.
Crossref
Crossref
R. S. Lanzman, M Notohamiprodjo & HJ Wittsack. (2015) Funktionelle Magnetresonanztomographie der NierenFunctional magnetic resonance imaging of the kidneys. Der Radiologe 55:12, pages 1077-1087.
Crossref
Crossref
T Y Jeon, C K Kim, J-H Kim, G H Im, B K Park & J H Lee. (2015) Assessment of early therapeutic response to sorafenib in renal cell carcinoma xenografts by dynamic contrast-enhanced and diffusion-weighted MR imaging. The British Journal of Radiology 88:1053, pages 20150163.
Crossref
Crossref
Xiaolin Zheng, Lihua Xiao, Xianmiao Fan, Ning Huang, Zihua Su & Xiao Xu. (2015) Free breathing DCE-MRI with motion correction and its values for benign and malignant liver tumor differentiation. Radiology of Infectious Diseases 2:2, pages 65-71.
Crossref
Crossref
Benjamin Lemasson, Audrey Bouchet, Cécile Maisin, Thomas Christen, Géraldine Le Duc, Chantal Rémy, Emmanuel L. Barbier & Raphaël Serduc. (2015) Multiparametric MRI as an early biomarker of individual therapy effects during concomitant treatment of brain tumours. NMR in Biomedicine 28:9, pages 1163-1173.
Crossref
Crossref
Keith T. FlahertyBetty K. HamiltonMark A. RosenRavi K. AmaravadiLynn M. SchuchterMaryann GallagherHelen Chen, Chandra SehgalPeter J. O'Dwyer. (2015) Phase I/II Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers. The Oncologist 20:8, pages 952-959.
Crossref
Crossref
Reshmi Rajendran, Jieming Liang, Mei Yee Annie Tang, Brian Henry & Kai-Hsiang Chuang. (2015) Optimization of arterial spin labeling MRI for quantitative tumor perfusion in a mouse xenograft model. NMR in Biomedicine 28:8, pages 988-997.
Crossref
Crossref
Viktor Gr?nwald, Rana R. McKay, Katherine M. Krajewski, Daniel Kalanovic, Xun Lin, Julia J. Perkins, Ronit Simantov & Toni K. Choueiri. (2015) Depth of Remission is a Prognostic Factor for Survival in Patients with Metastatic Renal Cell Carcinoma. European Urology 67:5, pages 952-958.
Crossref
Crossref
J. M. Winfield, G. S. Payne & N. M. deSouza. (2015) Functional MRI and CT biomarkers in oncology. European Journal of Nuclear Medicine and Molecular Imaging 42:4, pages 562-578.
Crossref
Crossref
Yan Wu, Young Suk Kwon, Mina Labib, David J. Foran & Eric A. Singer. (2015) Magnetic Resonance Imaging as a Biomarker for Renal Cell Carcinoma. Disease Markers 2015, pages 1-9.
Crossref
Crossref
Margarita Braunagel, Elisabeth Radler, Michael Ingrisch, Michael Staehler, Christine Schmid-Tannwald, Carsten Rist, Konstantin Nikolaou, Maximilian F. Reiser & Mike Notohamiprodjo. (2015) Dynamic Contrast-Enhanced Magnetic Resonance Imaging Measurements in Renal Cell Carcinoma. Investigative Radiology 50:1, pages 57-66.
Crossref
Crossref
Ping Wang, Yiqun Xue, Xia Zhao, Jiangsheng Yu, Mark Rosen & Hee Kwon Song. (2015) Effects of flip angle uncertainty and noise on the accuracy of DCE-MRI metrics: comparison between standard concentration-based and signal difference methods. Magnetic Resonance Imaging 33:1, pages 166-173.
Crossref
Crossref
Philipp Kickingereder, Benedikt Wiestler, Markus Graf, Sabine Heiland, Heinz Peter Schlemmer, Wolfgang Wick, Antje Wick, Martin Bendszus & Alexander Radbruch. (2014) Evaluation of dynamic contrast-enhanced MRI derived microvascular permeability in recurrent glioblastoma treated with bevacizumab. Journal of Neuro-Oncology 121:2, pages 373-380.
Crossref
Crossref
Guido H. Jajamovich, Claudia Calcagno, Hadrien A. Dyvorne, Henry Rusinek & Bachir Taouli. (2014) DCE-MRI of the Liver: Reconstruction of the Arterial Input Function Using a Low Dose Pre-Bolus Contrast Injection. PLoS ONE 9:12, pages e115667.
Crossref
Crossref
Saadia A Aziz, Joshua A Sznol, Laurence Albiges, Christopher Zito, Lucia B Jilaveanu, Robert L Camp, Bernard Escudier & Harriet M Kluger. (2014) Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma. Cancer Cell International 14:1.
Crossref
Crossref
Nathalie Lassau, Julia Bonastre, Mich?le Kind, Val?rie Vilgrain, Jo?lle Lacroix, Marie Cuinet, Sophie Taieb, Richard Aziza, Antony Sarran, Catherine Labbe-Devilliers, Benoit Gallix, Olivier Lucidarme, Yvette Ptak, Laurence Rocher, Louis-Michel Caquot, Sophie Chagnon, Denis Marion, Alain Luciani, Sylvaine Feutray, Jo?lle Uzan-Augui, Benedicte Coiffier, Baya Benastou & Serge Koscielny. (2014) Validation of Dynamic Contrast-Enhanced Ultrasound in Predicting Outcomes of Antiangiogenic Therapy for Solid Tumors. Investigative Radiology 49:12, pages 794-800.
Crossref
Crossref
M. A. Karajannis, G. Legault, M. J. Fisher, S. S. Milla, K. J. Cohen, J. H. Wisoff, D. H. Harter, J. D. Goldberg, T. Hochman, A. Merkelson, M. C. Bloom, A. J. Sievert, A. C. Resnick, G. Dhall, D. T. W. Jones, A. Korshunov, S. M. Pfister, C. G. Eberhart, D. Zagzag & J. C. Allen. (2014) Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. Neuro-Oncology 16:10, pages 1408-1416.
Crossref
Crossref
Johannes C. van der Mijn, James W. Mier, Henk J. Broxterman & Henk M. Verheul. (2014) Predictive biomarkers in renal cell cancer: Insights in drug resistance mechanisms. Drug Resistance Updates 17:4-6, pages 77-88.
Crossref
Crossref
Jill Rachel Mains, Frede Donskov, Erik Morre Pedersen, Hans Henrik Torp Madsen & Finn Rasmussen. (2014) Dynamic Contrast-Enhanced Computed Tomography as a Potential Biomarker in Patients With Metastatic Renal Cell Carcinoma. Investigative Radiology 49:9, pages 601-607.
Crossref
Crossref
Laia Valls, Christopher Hoimes, Andrew Sher, Lingzhi Hu, Zhenghong Lee, Raymond Muzic & Norbert Avril. (2014) Early Response Monitoring of Receptor Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma Using [F-18]Fluorothymidine-Positron Emission Tomography-Magnetic Resonance. Seminars in Roentgenology 49:3, pages 238-241.
Crossref
Crossref
Naveen S. Vasudev & Andrew R. Reynolds. (2014) Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis 17:3, pages 471-494.
Crossref
Crossref
Kyoung Doo SongDongil ChoiJung Hee LeeGeun Ho ImJehoon YangJae-Hun KimWon Jae Lee. (2014) Evaluation of Tumor Microvascular Response to Brivanib by Dynamic Contrast-Enhanced 7-T MRI in an Orthotopic Xenograft Model of Hepatocellular Carcinoma. American Journal of Roentgenology 202:6, pages W559-W566.
Crossref
Crossref
Louis de Mestier, Clarisse Dromain, Gaspard d'Assignies, Jean-Yves Scoazec, Nathalie Lassau, Rachida Lebtahi, Hedia Brixi, Emmanuel Mitry, Rosine Guimbaud, Frédéric Courbon, Michèle d'Herbomez & Guillaume Cadiot. (2014) Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art. Endocrine-Related Cancer 21:3, pages R105-R120.
Crossref
Crossref
F. Cornelis, H. de Clermont, J.C. Bernhard, A. Ravaud & N. Grenier. (2014) L’imagerie d’évaluation thérapeutique en pratique clinique d’oncologie urologique. Progrès en Urologie 24:7, pages 399-413.
Crossref
Crossref
Reinhard Meier, Rickmer Braren, Yvonne Kosanke, Johanna Bussemer, Frauke Neff, Moritz Wildgruber, Sarah Schwarzenb?ck, Annette Frank, Bernhard Haller, Andreas M. Hohlbaum, Markus Schwaiger, Hendrik Gille, Ernst J. Rummeny & Ambros J. Beer. (2014) Multimodality Multiparametric Imaging of Early Tumor Response to a Novel Antiangiogenic Therapy Based on Anticalins. PLoS ONE 9:5, pages e94972.
Crossref
Crossref
Tobias Heye, Daniel T. Boll, Caecilia S. Reiner, Mustafa R. Bashir, Brian M. Dale & Elmar M. Merkle. (2014)
Impact of precontrast T
10
relaxation times on dynamic contrast-enhanced MRI pharmacokinetic parameters: T
10
mapping versus a fixed T
10
reference value
. Journal of Magnetic Resonance Imaging 39:5, pages 1136-1145.
Crossref
Crossref
Felix Nensa, Jörg Stattaus, Bruno Morgan, Mark A Horsfield, Jean-Charles Soria, Benjamin Besse, Valerie Gounant, Antoine Khalil, Katja Seng, Berthold Fischer, Heiko Krissel, Dirk Laurent, Daniel Christoph, Wilfried EE Eberhardt & Thomas C Gauler. (2014) Dynamic contrast-enhanced MRI parameters as biomarkers for the effect of vatalanib in patients with non-small-cell lung cancer. Future Oncology 10:5, pages 823-833.
Crossref
Crossref
Bristi Basu, Swethajit Biswas & Simon PaceyJames PB O’Connor. 2014. Antiangiogenesis in Cancer Therapy. Antiangiogenesis in Cancer Therapy
29
48
.
Naomi Campbell, Andrew B. Rosenkrantz & Ivan Pedrosa. (2014) MRI Phenotype in Renal Cancer. Topics in Magnetic Resonance Imaging 23:2, pages 95-115.
Crossref
Crossref
Axel Bex, Laure Fournier, Nathalie Lassau, Peter Mulders, Paul Nathan, Wim J.G. Oyen & Thomas Powles. (2014) Assessing the Response to Targeted Therapies in Renal Cell Carcinoma: Technical Insights and Practical Considerations. European Urology 65:4, pages 766-777.
Crossref
Crossref
Lu?s Le?n, Roberto Garc?a-Figueras, Cristina Su?rez, Antonia Arjonilla, Javier Puente, Blanca Vargas, Maria Jos? M?ndez Vidal & Carmen Sebasti?. (2013) Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer. Targeted Oncology 9:1, pages 9-24.
Crossref
Crossref
Fiona M. Fennessy, Rana R. McKay, Clair J. Beard, Mary-Ellen Taplin & Clare M. Tempany. (2014) Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Prostate Cancer Clinical Trials: Potential Roles and Possible Pitfalls. Translational Oncology 7:1, pages 120-129.
Crossref
Crossref
N Bharwani, M E Miquel, T Powles, P Dilks, A Shawyer, A Sahdev, P D Wilson, S Chowdhury, D M Berney & A G Rockall. (2013) Diffusion-weighted and multiphase contrast-enhanced MRI as surrogate markers of response to neoadjuvant sunitinib in metastatic renal cell carcinoma. British Journal of Cancer 110:3, pages 616-624.
Crossref
Crossref
Margarita Braunagel, Anno Graser, Maximilian Reiser & Mike Notohamiprodjo. (2013) The role of functional imaging in the era of targeted therapy of renal cell carcinoma. World Journal of Urology 32:1, pages 47-58.
Crossref
Crossref
Kyung Ah Kim, Mi-Suk Park, Hyun-Jun Ji, Jun Yong Park, Kwang-Hyub Han, Myeong-Jin Kim & Ki Whang Kim. (2014) Diffusion and perfusion MRI prediction of progression-free survival in patients with hepatocellular carcinoma treated with concurrent chemoradiotherapy. Journal of Magnetic Resonance Imaging 39:2, pages 286-292.
Crossref
Crossref
A. Bockisch, M. Forsting, L.S. Freudenberg, T. Loch, H. Rübben & J. Stattaus. 2014. Uroonkologie. Uroonkologie
145
173
.
Carmen Sebastià, Antonio Luna, Pilar Paredes & Carlos Nicolau. 2014. Functional Imaging in Oncology. Functional Imaging in Oncology
1143
1171
.
A. Bockisch, M. Forsting, L.S. Freudenberg, T. Loch, H. Rübben & J. Stattaus. 2014. Uroonkologie. Uroonkologie
145
173
.
Christina M. Annunziata & Phillip A. Dennis. 2014. Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. Handbook of Anticancer Pharmacokinetics and Pharmacodynamics
1
21
.
Christine A. Ciunci, Rodolfo F. Perini, Anjali N. Avadhani, Hyunseon C. Kang, Weijing Sun, Maryann Redlinger, Kathleen Harlacker, Keith T. Flaherty, Bruce J. Giantonio, Mark A. Rosen, Chaitanya R. Divgi, Hee Kwon Song, Sarah Englander, Andrea Troxel, Mitchell Schnall & Peter J. O'Dwyer. (2014) Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer. Cancer 120:1, pages 77-85.
Crossref
Crossref
Saadia A Aziz, Joshua Sznol, Adebowale Adeniran, John W Colberg, Robert L Camp & Harriet M Kluger. (2013) Vascularity of primary and metastatic renal cell carcinoma specimens. Journal of Translational Medicine 11:1.
Crossref
Crossref
R K Kelley, J Hwang, M J M Magbanua, L Watt, J H Beumer, S M Christner, S Baruchel, B Wu, L Fong, B M Yeh, A P Moore, A H Ko, W M Korn, S Rajpal, J W Park, M A Tempero, A P Venook & E K Bergsland. (2013) A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. British Journal of Cancer 109:7, pages 1725-1734.
Crossref
Crossref
N S Vasudev, V Goh, J K Juttla, V L Thompson, J M G Larkin, M Gore, P D Nathan & A R Reynolds. (2013) Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy. British Journal of Cancer 109:5, pages 1230-1242.
Crossref
Crossref
M. Dror Michaelson & Walter M. Stadler. (2013) Predictive Markers in Advanced Renal Cell Carcinoma. Seminars in Oncology 40:4, pages 459-464.
Crossref
Crossref
Mike Notohamiprodjo, Michael Staehler, Nicole Steiner, Felix Schwab, Steven P. Sourbron, Henrik J. Michaely, Andreas D. Helck, Maximilian F. Reiser & Konstantin Nikolaou. (2013) Combined Diffusion-Weighted, Blood Oxygen Level–Dependent, and Dynamic Contrast-Enhanced MRI for Characterization and Differentiation of Renal Cell Carcinoma. Academic Radiology 20:6, pages 685-693.
Crossref
Crossref
James P. B. O'Connor & Geoff J. M. Parker. 2013. Clinical Perfusion MRI. Clinical Perfusion MRI
238
254
.
James O'Connor & Richard Carano. 2013. Quantifying Morphology and Physiology of the Human Body Using MRI. Quantifying Morphology and Physiology of the Human Body Using MRI
269
328
.
D.-A. Clevert, A. Sterzik, M. Braunagel, M. Notohamiprodjo & A. Graser. (2013) Moderne Bildgebung von NierentumorenModern imaging of kidney tumors. Der Urologe 52:4, pages 515-526.
Crossref
Crossref
Edward Ashton & Jonathan Riek. (2013) Advanced MR techniques in multicenter clinical trials. Journal of Magnetic Resonance Imaging 37:4, pages 761-769.
Crossref
Crossref
Paul Nathan & Anup Vinayan. (2012) Imaging techniques as predictive and prognostic biomarkers in renal cell carcinoma. Therapeutic Advances in Medical Oncology 5:2, pages 119-131.
Crossref
Crossref
Tobias Heye, Matthew S. Davenport, Jeffrey J. Horvath, Sebastian Feuerlein, Steven R. Breault, Mustafa R. Bashir, Elmar M. Merkle & Daniel T. Boll. (2013) Reproducibility of Dynamic Contrast-enhanced MR Imaging. Part I. Perfusion Characteristics in the Female Pelvis by Using Multiple Computer-aided Diagnosis Perfusion Analysis Solutions. Radiology 266:3, pages 801-811.
Crossref
Crossref
Tobias Heye, Elmar M. Merkle, Caecilia S. Reiner, Matthew S. Davenport, Jeffrey J. Horvath, Sebastian Feuerlein, Steven R. Breault, Peter Gall, Mustafa R. Bashir, Brian M. Dale, Atilla P. Kiraly & Daniel T. Boll. (2013) Reproducibility of Dynamic Contrast-enhanced MR Imaging. Part II. Comparison of Intra- and Interobserver Variability with Manual Region of Interest Placement versus Semiautomatic Lesion Segmentation and Histogram Analysis. Radiology 266:3, pages 812-821.
Crossref
Crossref
Chad R. Haney, Xiaobing Fan, Erica Markiewicz, Devkumar Mustafi, Gregory S. Karczmar & Walter M. Stadler. (2013) Monitoring Anti-Angiogenic Therapy in Colorectal Cancer Murine Model using Dynamic Contrast-Enhanced MRI — Comparing Pixel-by-Pixel with Region of Interest Analysis. Technology in Cancer Research & Treatment 12:1, pages 71-78.
Crossref
Crossref
Keith T. FlahertySandra J. LeeFengmin ZhaoLynn M. SchuchterLawrence FlahertyRichard KeffordMichael B. AtkinsPhilip LemingJohn M. Kirkwood. (2013) Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma. Journal of Clinical Oncology 31:3, pages 373-379.
Crossref
Crossref
Hyunseon Christine Kang, Kay-See Tan, Stephen M. Keefe, Daniel F. Heitjan, Evan S. Siegelman, Keith T. Flaherty, Peter J. O’Dwyer & Mark A. Rosen. (2013) MRI Assessment of Early Tumor Response in Metastatic Renal Cell Carcinoma Patients Treated With Sorafenib. American Journal of Roentgenology 200:1, pages 120-126.
Crossref
Crossref
James P.B. O'Connor & Gordon C. Jayson. (2012) Do Imaging Biomarkers Relate to Outcome in Patients Treated with VEGF Inhibitors?. Clinical Cancer Research 18:24, pages 6588-6598.
Crossref
Crossref
Hersh Chandarana, Stella K. Kang, Samson Wong, Henry Rusinek, Jeff L. Zhang, Shigeki Arizono, William C. Huang, Jonathan Melamed, James S. Babb, Edgar F. Suan, Vivian S. Lee & Eric E. Sigmund. (2012) Diffusion-Weighted Intravoxel Incoherent Motion Imaging of Renal Tumors With Histopathologic Correlation. Investigative Radiology 47:12, pages 688-696.
Crossref
Crossref
Toshinari Yamasaki, Tomomi Kamba, Toru Kanno, Takahiro Inoue, Noboru Shibasaki, Ryuichiro Arakaki, Tomomi Yamada, Keiichi Kondo, Toshiyuki Kamoto, Hiroyuki Nishiyama, Osamu Ogawa & Eijiro Nakamura. (2012)
Tumor microvasculature with endothelial fenestrations in
VHL
null clear cell renal cell carcinomas as a potent target of anti‐angiogenic therapy
. Cancer Science 103:11, pages 2027-2037.
Crossref
Crossref
Mostafa Analoui, Joseph Bronzino & Donald PetersonEdward Ashton & Vijay Shah. 2012. Medical Imaging. Medical Imaging
1
20
.
Walter M. Stadler. (2012) Optimal Use of Imaging to Guide Treatment Decisions for Kidney Cancer. American Society of Clinical Oncology Educational Book:32, pages 284-287.
Crossref
Crossref
S De Bruyne, N Van Damme, P Smeets, L Ferdinande, W Ceelen, J Mertens, C Van de Wiele, R Troisi, L Libbrecht, S Laurent, K Geboes & M Peeters. (2012) Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases. British Journal of Cancer 106:12, pages 1926-1933.
Crossref
Crossref
Stella K. Kang & Hersh Chandarana. (2012) Contemporary Imaging of the Renal Mass. Urologic Clinics of North America 39:2, pages 161-170.
Crossref
Crossref
O. Lucidarme. (2012) Quelle place pour l’imagerie fonctionnelle en 2012 dans le suivi des traitements antiantigiogéniques ?Functional imaging assessment of anti-angiogenic therapies: what is its place in 2012?. Oncologie 14:4, pages 248-256.
Crossref
Crossref
Sonia P. Li & Anwar R. Padhani. (2012) Tumor response assessments with diffusion and perfusion MRI. Journal of Magnetic Resonance Imaging 35:4, pages 745-763.
Crossref
Crossref
James P. B. O'Connor, Alan Jackson, Geoff J. M. Parker, Caleb Roberts & Gordon C. Jayson. (2012) Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nature Reviews Clinical Oncology 9:3, pages 167-177.
Crossref
Crossref
N Tunariu, S B Kaye & N M deSouza. (2012) Functional imaging: what evidence is there for its utility in clinical trials of targeted therapies?. British Journal of Cancer 106:4, pages 619-628.
Crossref
Crossref
Venkata S. Katabathina, Nathalie Lassau, Ivan Pedrosa, Chaan S. Ng & Srinivasa R. Prasad. (2011) Evaluation of Treatment Response in Patients with Metastatic Renal Cell Carcinoma: Role of State-of-the-Art Cross-Sectional Imaging. Current Urology Reports 13:1, pages 70-81.
Crossref
Crossref
Anthony G. Gilet, Stella K. Kang, Danny Kim & Hersh Chandarana. (2011) Advanced Renal Mass Imaging: Diffusion and Perfusion MRI. Current Urology Reports 13:1, pages 93-98.
Crossref
Crossref
Julien EdelineElodie VauléonNathalie Rioux-LeclercqChristophe PerrinCécile Vigneau Karim BensalahBrigitte Laguerre. (2012) Safety and Efficacy of Sorafenib in Renal Cell Carcinoma. Cancer Growth and Metastasis 5, pages CGM.S7526.
Crossref
Crossref
Cinzia Ortega, Camillo Porta, Manuela Racca & Filippo Russo. 2012. Imaging Tumor Response to Therapy. Imaging Tumor Response to Therapy
61
75
.
S. Mehta, N. P. Hughes, F. M. Buffa, S. P. Li, R. F. Adams, A. Adwani, N. J. Taylor, N. C. Levitt, A. R. Padhani, A. Makris & A. L. Harris. (2011) Assessing Early Therapeutic Response to Bevacizumab in Primary Breast Cancer Using Magnetic Resonance Imaging and Gene Expression Profiles. JNCI Monographs 2011:43, pages 71-74.
Crossref
Crossref
Chao-Yu Hsu, Ying-Chun Shen, Chih-Wei Yu, Chiun Hsu, Fu-Chang Hu, Chih-Hung Hsu, Bang-Bin Chen, Shwu-Yuan Wei, Ann-Lii Cheng & Tiffany Ting-Fang Shih. (2011) Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. Journal of Hepatology 55:4, pages 858-865.
Crossref
Crossref
M. Ahmed, Y. Barbachano, A. Riddell, J. Hickey, K. L. Newbold, A. Viros, K. J. Harrington, R. Marais & C. M. Nutting. (2011) Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. European Journal of Endocrinology 165:2, pages 315-322.
Crossref
Crossref
Katherine M. Krajewski, Angela A. Giardino, Katherine Zukotynski, Annick D. Van den Abbeele & Ivan Pedrosa. (2011) Imaging in Renal Cell Carcinoma. Hematology/Oncology Clinics of North America 25:4, pages 687-715.
Crossref
Crossref
Sonia P. Li, Andreas Makris, Mark J. Beresford, N. Jane Taylor, Mei-Lin W. Ah-See, J. James Stirling, James A. d?Arcy, David J. Collins, Robert Kozarski & Anwar R. Padhani. (2011) Use of Dynamic Contrast-enhanced MR Imaging to Predict Survival in Patients with Primary Breast Cancer Undergoing Neoadjuvant Chemotherapy. Radiology 260:1, pages 68-78.
Crossref
Crossref
D.J. Jonker, L.S. Rosen, M.B. Sawyer, F. de Braud, G. Wilding, C.J. Sweeney, G.C. Jayson, G.A. McArthur, G. Rustin, G. Goss, J. Kantor, L. Velasquez, S. Syed, O. Mokliatchouk, D.M. Feltquate, G. Kollia, D.S.A. Nuyten & S. Galbraith. (2011) A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. Annals of Oncology 22:6, pages 1413-1419.
Crossref
Crossref
Benjamin Lemasson, Thomas Christen, Xavier Tizon, Régine Farion, Nadège Fondraz, Peggy Provent, Christoph Segebarth, Emmanuel L. Barbier, Philippe Genne, Olivier Duchamp & Chantal Remy. (2011) Assessment of multiparametric MRI in a human glioma model to monitor cytotoxic and anti-angiogenic drug effects. NMR in Biomedicine 24:5, pages 473-482.
Crossref
Crossref
S. Chawla, S. Kim, L.A. Loevner, W.-T. Hwang, G. Weinstein, A. Chalian, H. Quon & H. Poptani. (2011) Prediction of Disease-Free Survival in Patients with Squamous Cell Carcinomas of the Head and Neck Using Dynamic Contrast-Enhanced MR Imaging. American Journal of Neuroradiology 32:4, pages 778-784.
Crossref
Crossref
Alexander R. Guimaraes, Robert Ross, Jose L. Figuereido, Peter Waterman & Ralph Weissleder. (2010) MRI with Magnetic Nanoparticles Monitors Downstream Anti-Angiogenic Effects of mTOR Inhibition. Molecular Imaging and Biology 13:2, pages 314-320.
Crossref
Crossref
Emilio Sacco, Francesco Pinto, Angelo Totaro, Alessandro D’Addessi, Marco Racioppi, Gaetano Gulino, Andrea Volpe, Francesco Marangi, Daniele D’Agostino & Pierfrancesco Bassi. (2011) Imaging of Renal Cell Carcinoma: State of the Art and Recent Advances. Urologia Internationalis 86:2, pages 125-139.
Crossref
Crossref
Mike Notohamiprodjo, Maximilian F. Reiser & Steven P. Sourbron. (2010) Diffusion and perfusion of the kidney. European Journal of Radiology 76:3, pages 337-347.
Crossref
Crossref
Francesco Bertolini, Paola Marighetti & Yuval Shaked. (2010) Cellular and soluble markers of tumor angiogenesis: From patient selection to the identification of the most appropriate postresistance therapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1806:2, pages 131-137.
Crossref
Crossref
Benjamin Lemasson, Raphaël Serduc, Cécile Maisin, Audrey Bouchet, Nicolas Coquery, Philippe Robert, Géraldine Le Duc, Irène Troprès, Chantal Rémy & Emmanuel L. Barbier. (2010) Monitoring Blood-Brain Barrier Status in a Rat Model of Glioma Receiving Therapy: Dual Injection of Low-Molecular-Weight and Macromolecular MR Contrast Media. Radiology 257:2, pages 342-352.
Crossref
Crossref
Yan Chen, Jin Zhang, Jingrui Dai, Xiaoli Feng, Haizhen Lu & Chunwu Zhou. (2009) Angiogenesis of renal cell carcinoma: perfusion CT findings. Abdominal Imaging 35:5, pages 622-628.
Crossref
Crossref
M. Bellomi, S. Viotti, L. Preda, G. D’Andrea, L. Bonello & G. Petralia. (2010) Perfusion CT in solid body-tumours part II. Clinical applications and future developmentLa TC perfusionale nei tumori solidi del corpo parte II. Applicazioni cliniche e prospettive. La radiologia medica 115:6, pages 858-874.
Crossref
Crossref
M. Fatih Akisik, Kumaresan Sandrasegaran, Guixue Bu, Chen Lin, Gary D. Hutchins & Elena G. Chiorean. (2010) Pancreatic Cancer: Utility of Dynamic Contrast-enhanced MR Imaging in Assessment of Antiangiogenic Therapy. Radiology 256:2, pages 441-449.
Crossref
Crossref
Martin Zweifel & Anwar R. Padhani. (2010) Perfusion MRI in the early clinical development of antivascular drugs: decorations or decision making tools?. European Journal of Nuclear Medicine and Molecular Imaging 37:S1, pages 164-182.
Crossref
Crossref
James A. Fagin, R. Michael Tuttle & David G. Pfister. (2010) Harvesting the Low-Hanging Fruit: Kinase Inhibitors for Therapy of Advanced Medullary and Nonmedullary Thyroid Cancer. The Journal of Clinical Endocrinology & Metabolism 95:6, pages 2621-2624.
Crossref
Crossref
Astrid A. M. van der Veldt, Martijn R. Meijerink, Alfons J. M. van den Eertwegh & Epie Boven. (2010) Targeted therapies in renal cell cancer: recent developments in imaging. Targeted Oncology 5:2, pages 95-112.
Crossref
Crossref
Terence O'Reilly & Paul M.J. McSheehy. (2010) Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals. Translational Oncology 3:2, pages 65-79.
Crossref
Crossref
Joaquim Bellmunt, José Manuel Trigo, Emiliano Calvo, Joan Carles, José L Pérez-Gracia, Jordi Rubió, Juan Antonio Virizuela, Rafael López, Martín Lázaro & Joan Albanell. (2010) Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). The Lancet Oncology 11:4, pages 350-357.
Crossref
Crossref
Anwar R. Padhani & Aftab Alam Khan. (2010) Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for monitoring anticancer therapy. Targeted Oncology 5:1, pages 39-52.
Crossref
Crossref
Ying-Kiat Zee, James P. B. O'Connor, Geoff J. M. Parker, Alan Jackson, Andrew R. Clamp, M. Ben Taylor, Noel W. Clarke & Gordon C. Jayson. (2010) Imaging angiogenesis of genitourinary tumors. Nature Reviews Urology 7:2, pages 69-82.
Crossref
Crossref
Mike Notohamiprodjo, Steven Sourbron, Michael Staehler, Henrik J. Michaely, Ulrike I. Attenberger, Gerwin P. Schmidt, Holger Boehm, Annie Horng, Christian Glaser, Christian Stief, Maximilian F. Reiser & Karin A. Herrmann. (2010) Measuring perfusion and permeability in renal cell carcinoma with dynamic contrast‐enhanced MRI: A pilot study. Journal of Magnetic Resonance Imaging 31:2, pages 490-501.
Crossref
Crossref
Jean-Pascal H. MachielsStéphanie HenrySylvie ZanettaMarie-Christine KaminskyNicolas MichouxDenis RommelSandra SchmitzEmmanuelle BompasAnne-Françoise DilliesSandrine FaivreAnne MoxhonThierry DuprezJoel Guigay. (2010) Phase II Study of Sunitinib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: GORTEC 2006-01. Journal of Clinical Oncology 28:1, pages 21-28.
Crossref
Crossref
Paul M.J. McSheehy, Claudia Weidensteiner, Catherine Cannet, Stephane Ferretti, Didier Laurent, Stephan Ruetz, Michael Stumm & Peter R. Allegrini. (2010) Quantified Tumor T1 Is a Generic Early-Response Imaging Biomarker for Chemotherapy Reflecting Cell Viability. Clinical Cancer Research 16:1, pages 212-225.
Crossref
Crossref
N Murukesh, C Dive & G C Jayson. (2009) Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. British Journal of Cancer 102:1, pages 8-18.
Crossref
Crossref
W. Kimryn Rathmell, Raj Pruthi & Eric Wallen. (2010) Neoadjuvant treatment of renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations 28:1, pages 69-73.
Crossref
Crossref
Torsten Kessler, Michael Bayer, Christian Schwöppe, Rüdiger Liersch, Rolf M. Mesters & Wolfgang E. Berdel. 2010. Angiogenesis Inhibition. Angiogenesis Inhibition
137
163
.
Kyung Seok Han, Dae Chul Jung, Hyuck Jae Choi, Min Soo Jeong, Kang Su Cho, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee & Jinsoo Chung. (2010) Pretreatment assessment of tumor enhancement on contrast-enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving antiangiogenic therapy. Cancer, pages NA-NA.
Crossref
Crossref
T Minowa, K Kawano, H Kuribayashi, K Shiraishi, T Sugino, Y Hattori, M Yokoyama & Y Maitani. (2009) Increase in tumour permeability following TGF-β type I receptor-inhibitor treatment observed by dynamic contrast-enhanced MRI. British Journal of Cancer 101:11, pages 1884-1890.
Crossref
Crossref
Dennis Vriens, Hanneke W.M. van Laarhoven, Jack J.A. van Asten, Paul F.M. Krabbe, Eric P. Visser, Arend Heerschap, Cornelis J.A. Punt, Lioe-Fee de Geus-Oei & Wim J.G. Oyen. (2009)
Chemotherapy Response Monitoring of Colorectal Liver Metastases by Dynamic Gd-DTPA–Enhanced MRI Perfusion Parameters and
18
F-FDG PET Metabolic Rate
. Journal of Nuclear Medicine 50:11, pages 1777-1784.
Crossref
Crossref
Da-Liang Ou, Ying-Chun Shen, Ja-Der Liang, Jun-Yang Liou, Sung-Liang Yu, Hsiang-Hsuan Fan, Da-Sheng Wang, Yen-Shen Lu, Chiun Hsu & Ann-Lii Cheng. (2009) Induction of Bim Expression Contributes to the Antitumor Synergy Between Sorafenib and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Inhibitor CI-1040 in Hepatocellular Carcinoma. Clinical Cancer Research 15:18, pages 5820-5828.
Crossref
Crossref
Stephane Ferretti, Peter R. Allegrini, Mike M. Becquet & Paul M.J. McSheehy. (2009) Tumor Interstitial Fluid Pressure as an Early-Response Marker for Anticancer Therapeutics. Neoplasia 11:9, pages 874-881.
Crossref
Crossref
Gairin Dancey, Richard H. Begent & Tim Meyer. (2009) Imaging in targeted delivery of therapy to cancer. Targeted Oncology 4:3, pages 201-217.
Crossref
Crossref
Nyree Griffin, Lee Alexander Grant, Nishat Bharwani & S. Aslam Sohaib. (2009) Computed Tomography in Metastatic Renal Cell Carcinoma. Seminars in Ultrasound, CT and MRI 30:4, pages 359-366.
Crossref
Crossref
Roy S. HerbstDavid HongLinnea ChapRazelle KurzrockEdward JacksonJeffrey M. SilvermanErik RasmussenYu-Nien SunDon ZhongYuying C. HwangJeffrey L. EvelhochJonathan D. OlinerNgocDiep LeLee S. Rosen. (2009) Safety, Pharmacokinetics, and Antitumor Activity of AMG 386, a Selective Angiopoietin Inhibitor, in Adult Patients With Advanced Solid Tumors. Journal of Clinical Oncology 27:21, pages 3557-3565.
Crossref
Crossref
I.M.E. Desar, C.M.L. van Herpen, H.W.M. van Laarhoven, J.O. Barentsz, W.J.G. Oyen & W.T.A. van der Graaf. (2009) Beyond RECIST: Molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treatment Reviews 35:4, pages 309-321.
Crossref
Crossref
Benjamin M. Yeh. (2009) Invited Commentary. RadioGraphics 29:3, pages 755-757.
Crossref
Crossref
A.C. Backen, J. Cummings, C. Mitchell, G. Jayson, T.H. Ward & C. Dive. (2009) ‘Fit-for-purpose’ validation of SearchLight multiplex ELISAs of angiogenesis for clinical trial use. Journal of Immunological Methods 342:1-2, pages 106-114.
Crossref
Crossref
Peter C. Adamson. (2008) Imaging in early phase childhood cancer trials. Pediatric Radiology 39:S1, pages 38-41.
Crossref
Crossref
Andreas Bockisch, Michael Forsting, Lutz S. Freudenberg, Tilmann Loch, Herbert Rübben & Jörg Stattaus. 2009. Uroonkologie. Uroonkologie
47
71
.
Scott M. Wilhelm, Lila Adnane, Philippa Newell, Augusto Villanueva, Josep M. Llovet & Mark Lynch. (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Molecular Cancer Therapeutics 7:10, pages 3129-3140.
Crossref
Crossref
James PB O'Connor, Alan Jackson, Marie-Claude Asselin, David L Buckley, Geoff JM Parker & Gordon C Jayson. (2008) Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives. The Lancet Oncology 9:8, pages 766-776.
Crossref
Crossref
Haiyan Chen, Jian Zhang, Zhiyu Qian, Fei Liu, Xinyang Chen, Yuzhu Hu & Yueqing Gu. (2008)
In vivo
non-invasive optical imaging of temperature-sensitive co-polymeric nanohydrogel
. Nanotechnology 19:18, pages 185707.
Crossref
Crossref